Type 1 diabetes immunotherapy using polyclonal regulatory T cells

Autologous regulatory T cells can be expanded and are well tolerated in patients with recent-onset type 1 diabetes. Regulating type 1 diabetes In patients with type 1 diabetes (T1D), immune cells attack the insulin-producing β cells of the pancreas. The resulting prolonged increase in blood sugar levels can lead to serious complications including heart disease and kidney failure. Regulatory T cells (Tregs) have been shown to be defective in autoimmune diseases. Now, Bluestone et al. report a phase 1 trial of adoptive Treg immunotherapy to repair or replace Tregs in type 1 diabetics. The ex vivo–expanded polyclonal Tregs were long-lived after transfer and retained a broad Treg phenotype long-term. Moreover, the therapy was safe, supporting efficacy testing in further trials. Type 1 diabetes (T1D) is an autoimmune disease that occurs in genetically susceptible individuals. Regulatory T cells (Tregs) have been shown to be defective in the autoimmune disease setting. Thus, efforts to repair or replace Tregs in T1D may reverse autoimmunity and protect the remaining insulin-producing β cells. On the basis of this premise, a robust technique has been developed to isolate and expand Tregs from patients with T1D. The expanded Tregs retained their T cell receptor diversity and demonstrated enhanced functional activity. We report on a phase 1 trial to assess safety of Treg adoptive immunotherapy in T1D. Fourteen adult subjects with T1D, in four dosing cohorts, received ex vivo–expanded autologous CD4+CD127lo/−CD25+ polyclonal Tregs (0.05 × 108 to 26 × 108 cells). A subset of the adoptively transferred Tregs was long-lived, with up to 25% of the peak level remaining in the circulation at 1 year after transfer. Immune studies showed transient increases in Tregs in recipients and retained a broad Treg FOXP3+CD4+CD25hiCD127lo phenotype long-term. There were no infusion reactions or cell therapy–related high-grade adverse events. C-peptide levels persisted out to 2+ years after transfer in several individuals. These results support the development of a phase 2 trial to test efficacy of the Treg therapy.

[1]  Jonathan H. Esensten,et al.  Plasticity of Human Regulatory T Cells in Healthy Subjects and Patients with Type 1 Diabetes , 2011, The Journal of Immunology.

[2]  Christian Schmidl,et al.  Dominant Th2 Differentiation of Human Regulatory T Cells upon Loss of FOXP3 Expression , 2012, The Journal of Immunology.

[3]  D. Klatzmann,et al.  The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases , 2015, Nature Reviews Immunology.

[4]  J. Bluestone,et al.  Regulatory T cells: stability revisited. , 2011, Trends in immunology.

[5]  K. Cerosaletti,et al.  Defects in IL-2R Signaling Contribute to Diminished Maintenance of FOXP3 Expression in CD4+CD25+ Regulatory T-Cells of Type 1 Diabetic Subjects , 2009, Diabetes.

[6]  Qizhi Tang,et al.  The Foxp3+ regulatory T cell: a jack of all trades, master of regulation , 2008, Nature Immunology.

[7]  G. Szot,et al.  Expansion of Human Regulatory T-Cells From Patients With Type 1 Diabetes , 2009, Diabetes.

[8]  David M Maahs,et al.  Current State of Type 1 Diabetes Treatment in the U.S.: Updated Data From the T1D Exchange Clinic Registry , 2015, Diabetes Care.

[9]  B. Hall,et al.  Specific unresponsiveness in rats with prolonged cardiac allograft survival after treatment with cyclosporine. III. Further characterization of the CD4+ suppressor cell and its mechanisms of action , 1990, The Journal of experimental medicine.

[10]  Jeffrey A. Bluestone,et al.  In Vitro–expanded Antigen-specific Regulatory T Cells Suppress Autoimmune Diabetes , 2004, The Journal of experimental medicine.

[11]  M. Foss,et al.  Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. , 2009, JAMA.

[12]  J. Bluestone,et al.  Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. , 2008, Immunity.

[13]  H. Waldmann,et al.  Harnessing FOXP3+ regulatory T cells for transplantation tolerance. , 2014, The Journal of clinical investigation.

[14]  Jeffrey A. Bluestone,et al.  Genetics, pathogenesis and clinical interventions in type 1 diabetes , 2010, Nature.

[15]  Bruce R. Blazar,et al.  Massive ex Vivo Expansion of Human Natural Regulatory T Cells (Tregs) with Minimal Loss of in Vivo Functional Activity , 2011, Science Translational Medicine.

[16]  M. Hellerstein,et al.  Measurement of cell proliferation by labeling of DNA with stable isotope-labeled glucose: studies in vitro, in animals, and in humans. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[17]  C. Beam,et al.  Fall in C-Peptide During First 2 Years From Diagnosis , 2012, Diabetes.

[18]  A. Lares,et al.  Clinical Grade Manufacturing of Human Alloantigen‐Reactive Regulatory T Cells for Use in Transplantation , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[19]  M. Toda,et al.  Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. , 1995, Journal of immunology.

[20]  M. Rigby,et al.  Targeting Memory T Cells in Type 1 Diabetes , 2015, Current Diabetes Reports.

[21]  R. Dana,et al.  CCL-21 Conditioned Regulatory T Cells Induce Allotolerance through Enhanced Homing to Lymphoid Tissue , 2014, The Journal of Immunology.

[22]  J. Bluestone,et al.  Rapamycin/IL-2 Combination Therapy in Patients With Type 1 Diabetes Augments Tregs yet Transiently Impairs β-Cell Function , 2012, Diabetes.

[23]  W. Młynarski,et al.  Therapy of type 1 diabetes with CD4(+)CD25(high)CD127-regulatory T cells prolongs survival of pancreatic islets - results of one year follow-up. , 2014, Clinical immunology.

[24]  M. Hellerstein,et al.  Measurement of cell proliferation by heavy water labeling , 2007, Nature Protocols.

[25]  Jeffrey N. Martin,et al.  CD56negCD16+ NK cells are activated mature NK cells with impaired effector function during HIV-1 infection , 2013, Retrovirology.

[26]  Qizhi Tang,et al.  Regulatory T-cell therapy in transplantation: moving to the clinic. , 2013, Cold Spring Harbor perspectives in medicine.

[27]  S. Ziegler,et al.  Defective regulatory and effector T cell functions in patients with FOXP3 mutations. , 2006, The Journal of clinical investigation.

[28]  Jeffrey N. Martin,et al.  CD 56 negCD 16 + NK cells are activated mature NK cells with impaired effector function during HIV-1 infection , 2014 .

[29]  W. Hagopian,et al.  Teplizumab (Anti-CD3 mAb) Treatment Preserves C-Peptide Responses in Patients With New-Onset Type 1 Diabetes in a Randomized Controlled Trial , 2013, Diabetes.

[30]  I. Türbachova,et al.  DNA demethylation in the human FOXP3 locus discriminates regulatory T cells from activated FOXP3+ conventional T cells , 2007, European journal of immunology.

[31]  J. Wagner,et al.  Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. , 2011, Blood.

[32]  J. Bluestone,et al.  The therapeutic potential of regulatory T cells for the treatment of autoimmune disease , 2015, Expert opinion on therapeutic targets.

[33]  A. Mackensen,et al.  Survival and Tumor Localization of Adoptively Transferred Melan-A-Specific T Cells in Melanoma Patients 1 , 2003, The Journal of Immunology.

[34]  Baiming Zou,et al.  Anti-thymocyte globulin/G-CSF treatment preserves β cell function in patients with established type 1 diabetes. , 2015, The Journal of clinical investigation.

[35]  S. Wild,et al.  Glycaemic control of Type 1 diabetes in clinical practice early in the 21st century: an international comparison , 2015, Diabetic medicine : a journal of the British Diabetic Association.

[36]  R. Nussenblatt,et al.  Standardizing immunophenotyping for the Human Immunology Project , 2012, Nature Reviews Immunology.

[37]  R. Flavell,et al.  CD4+CD25+ T regulatory cells control anti-islet CD8+ T cells through TGF-β–TGF-β receptor interactions in type 1 diabetes , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[38]  Mark S. Anderson,et al.  T cells in the control of organ-specific autoimmunity. , 2015, The Journal of clinical investigation.

[39]  Bart Nooteboom,et al.  An International Comparison , 2000 .

[40]  W. Młynarski,et al.  Administration of CD4+CD25highCD127− Regulatory T Cells Preserves β-Cell Function in Type 1 Diabetes in Children , 2012, Diabetes Care.

[41]  J. Chen,et al.  Targeted Disruption of CD38 Accelerates Autoimmune Diabetes in NOD/Lt Mice by Enhancing Autoimmunity in an ADP-Ribosyltransferase 2-Dependent Fashion1 , 2006, The Journal of Immunology.

[42]  Jeffrey N. Martin,et al.  CD56 neg CD16 + NK cells are activated mature NK cells with impaired effector function during HIV-1 infection , 2014 .

[43]  J. Buckner,et al.  Assessment of suppressive capacity by human regulatory T cells using a reproducible, bi-directional CFSE-based in vitro assay. , 2011, Methods in molecular biology.

[44]  T. Gingeras,et al.  CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells , 2006, The Journal of experimental medicine.

[45]  P. Raskin,et al.  Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial. , 2013, The lancet. Diabetes & endocrinology.

[46]  L. Chiriboga,et al.  Peripheral CD4(+)CD8(+) T cells are differentiated effector memory cells with antiviral functions. , 2004, Blood.